Clinical Trial

Secura Bio Announces NCCN® Duvelisib (COPIKTRA®) Update to Clinical Practice Guidelines in Oncology for Cutaneous T-Cell Lymphoma (CTCL), Including Mycosis Fungoides and Sézary Syndrome

BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes…

6 days ago

Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program

License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI…

6 days ago

4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease

Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through 1 year at dose selected for Phase…

6 days ago

Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease

NESS ZIONA, Israel, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients…

6 days ago

Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress

-- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in…

6 days ago

Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients

Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral rebounds Activity shown in Paxlovid®-ineligible patients,…

6 days ago

Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California

VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”),…

6 days ago

BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or…

6 days ago

numares Health enters ASEAN region with regulatory approval in Malaysia and first contract win for AXINON® LDLp Test System

AXINON® LDLp Test System receives Medical Device Authority (MDA) in Malaysianumares Health appoints BioD Medica for local distribution MDA filing…

6 days ago

numares Health enters ASEAN region with regulatory approval in Malaysia and first contract win for AXINON® LDLp Test System

AXINON® LDLp Test System receives Medical Device Authority (MDA) in Malaysianumares Health appoints BioD Medica for local distribution MDA filing…

6 days ago